catalyst

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia — primary completion

as of 2026-07-01
at a glance
2008-10 · ActualThis event happened.
Synthesized from structured facts only — each point cited above.

Event

What
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia — primary completion
Type
Trial Readout
Date
2008-10
Date type
ACTUAL
Phase
Phase 2
This event happened.